StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2022 - 01 - 18
1
2021 - 10 - 14
1
2021 - 10 - 13
1
2021 - 09 - 13
1
2021 - 09 - 01
1
2021 - 08 - 24
1
2021 - 07 - 29
1
2021 - 06 - 10
1
2021 - 05 - 20
2
2021 - 03 - 29
1
Sector
Communications
3
Manufacturing
11
Tags
100
1
Acquisition
1
Africa
2
Alliances
1
Als
1
Application
4
Approval
1
Asco
3
Authorized
3
Awards
1
Biotech
3
Biotech-bay
1
Biotech-beach
10
Bladder
13
Bladder cancer
3
Breast cancer
1
Cancer
29
Cel
3
Cell
1
Ces
1
Clinical trials
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
4
Commercialization
1
Conference
6
Covid
8
Covid-19
2
Deadline
2
Disease
5
Enroll
5
Fda
5
Hiv
4
Iot
3
License
4
Lung cancer
2
Media
3
Money
2
N/a
55
Natural
2
Pancreas
3
Pancreatic
6
Phase 1
3
Phase 2
11
Phase 2/3
3
Phase 3
3
Plus
4
Positive
3
Presentation
3
Research
6
Response
2
Resubmission
2
Results
6
Study
5
T-cell
5
Technology
2
Therapy
8
Trial
18
Trials
2
Update
2
Vaccine
10
Entities
Addex therapeutics ltd
8
Advaxis, inc.
9
Adverum biotechnologies, inc.
8
Aldeyra therapeutics, inc.
9
Algernon pharmaceuticals inc.
19
Alnylam pharmaceuticals, inc.
11
Alterity therapeutics limited
25
Altimmune, inc.
12
Amgen inc.
15
Anavex life sciences corp.
11
Arrowhead pharmaceuticals, inc.
17
Athira pharma, inc.
10
Atossa therapeutics, inc.
11
Ayala pharmaceuticals, inc.
14
Beigene, ltd.
8
Biogen inc.
13
Biophytis - adr
8
Biorestorative therapies, inc.
10
Biovie inc.
8
Bridgebio pharma, inc.
11
Bristol-myers squibb company
15
Clene inc
15
Cognition therapeutics inc
8
Curevac n.v.
11
Denali therapeutics inc.
8
Dynavax technologies corporation
12
Eli lilly and company
34
Eloxx pharmaceuticals, inc.
11
Entera bio ltd.
8
Evelo biosciences, inc.
9
First wave biopharma, inc.
13
G1 therapeutics, inc.
9
Galecto, inc.
8
Gilead sciences, inc.
9
Hepion pharmaceuticals, inc.
10
I-mab
26
Ideaya biosciences, inc.
13
Immunic, inc.
11
Immunitybio inc
11
Incyte corporation
19
Johnson & johnson
28
Kintara therapeutics, inc.
8
Lipocine inc.
8
Longeveron llc - class a
13
Mediwound ltd.
13
Metacrine, inc.
10
Moderna, inc.
13
Mymd pharmaceuticals inc
8
Ocuphire pharma inc.
12
Orange
8
Pds biotechnology corporation
15
Pfizer, inc.
12
Protagonist therapeutics, inc.
10
Redhill biopharma ltd.
16
Sanofi
43
Scholar rock holding corporation
8
Sorrento therapeutics, inc.
20
Springworks therapeutics, inc.
9
Todos medical ltd.
8
Vir biotechnology, inc.
10
Symbols
FNCTF
3
IBRX
11
Exchanges
Nasdaq
11
Crawled Date
2022 - 01 - 19
1
2021 - 10 - 14
1
2021 - 10 - 13
1
2021 - 09 - 13
1
2021 - 09 - 01
1
2021 - 08 - 24
1
2021 - 07 - 29
1
2021 - 06 - 10
1
2021 - 05 - 20
2
2021 - 03 - 29
1
Crawled Time
00:00
1
13:00
5
13:15
2
14:00
2
20:00
1
Source
www.biospace.com
6
www.nantkwest.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 2
entities :
Immunitybio inc
save search
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published:
2022-01-18
(Crawled : 00:00)
- biospace.com/
FNCTF
|
News
|
$11.0354
-20.84%
320
|
Communications
|
-2.34%
|
O:
-0.4%
H:
0.0%
C:
-0.58%
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-21.44%
|
O:
-1.27%
H:
0.0%
C:
0.0%
phase 2
trial
disease
media
asco
cancer
pancreatic
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
Published:
2021-10-14
(Crawled : 13:00)
- biospace.com/
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-42.42%
|
O:
0.99%
H:
8.76%
C:
4.24%
treatment
phase 2
cancer
pancreatic
pancreas
enroll
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
Published:
2021-10-13
(Crawled : 13:00)
- nantkwest.com
FNCTF
|
News
|
$11.0354
-20.84%
320
|
Communications
|
0.78%
|
O:
-0.18%
H:
0.0%
C:
0.0%
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-43.35%
|
O:
0.54%
H:
0.59%
C:
-2.15%
phase 2
cancer
vaccine
pancreatic
pancreas
enroll
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published:
2021-09-13
(Crawled : 13:00)
- nantkwest.com
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-47.02%
|
O:
0.81%
H:
3.11%
C:
-2.01%
media
phase 2
phase 2/3
positive
cancer
trial
response
bladder
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
Published:
2021-09-01
(Crawled : 13:00)
- nantkwest.com
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-53.95%
|
O:
0.97%
H:
3.13%
C:
2.7%
presentation
phase 2
phase 2/3
results
cancer
trial
trial results
bladder
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
Published:
2021-08-24
(Crawled : 13:00)
- biospace.com/
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-51.75%
|
O:
0.28%
H:
4.22%
C:
3.49%
disease
phase 2
phase 2/3
results
trial
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
Published:
2021-07-29
(Crawled : 20:00)
- biospace.com/
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-54.36%
|
O:
0.61%
H:
1.47%
C:
-3.12%
phase 2
results
cancer
trial
pancreatic
pancreas
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
Published:
2021-06-10
(Crawled : 13:15)
- nantkwest.com
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-65.93%
|
O:
0.2%
H:
2.21%
C:
-3.24%
phase 2
phase 1
therapy
hiv
phase 3
injection
infections
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types
Published:
2021-05-20
(Crawled : 14:00)
- biospace.com/
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-67.17%
|
O:
0.19%
H:
9.44%
C:
6.5%
disease
phase 2
lung cancer
cancer
enroll
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
Published:
2021-05-20
(Crawled : 13:15)
- nantkwest.com
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-67.17%
|
O:
0.19%
H:
9.44%
C:
6.5%
disease
phase 2
lung cancer
therapy
cancer
enroll
ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
Published:
2021-03-29
(Crawled : 14:00)
- biospace.com/
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
-80.43%
|
O:
5.86%
H:
2.22%
C:
-13.02%
vaccine
phase 1
phase 3
phase 2
cancer
immunotherapy
prostate cancer
therapy
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.